Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:47 PM
Ignite Modification Date:
2025-12-24 @ 10:47 PM
NCT ID:
NCT06081569
Eligibility Criteria:
Inclusion Criteria:
1. . Participants' age is between 50 and 85 years old, male or female;
2. . Participants graduated from primary school or above, with normal hearing, vision, and pronunciation, using Chinese as their mother tongue and Mandarin as their daily languageļ¼
3. . The diagnosis of AD and MCI participants conform to the corresponding diagnostic criteria mentioned above;
4. . The scores of MMSE are between 10 and 28, and the scores of CDR are no more than 2.
5. . Patients or family members agree to sign informed consent.
Exclusion Criteria:
1. . Participants suffer from neurological disorders that could cause dysfunction of the brain, such as depression, tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal cranial pressure hydrocephalus, and so forth;
2. . Participants suffer from systematic diseases that could cause cognitive impairment, such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, and so forth;
3. . Participants suffer from diseases that are unable to cooperate with the examinations;
4. . Participants cannot take magnetic resonance imaging;
5. . Participants suffer from mental and neurodevelopmental retardation;
6. . Participants refuse to sign informed consent.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
50 Years
Maximum Age:
85 Years
Study:
NCT06081569
Study Brief:
Protocol Section:
NCT06081569